Compare GDOT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | ABUS |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.2M | 836.0M |
| IPO Year | 2010 | 2008 |
| Metric | GDOT | ABUS |
|---|---|---|
| Price | $12.22 | $4.07 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.13 | N/A |
| AVG Volume (30 Days) | 294.4K | ★ 2.8M |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | 0.33 | ★ 0.84 |
| Revenue | ★ $2,080,491,000.00 | $14,083,000.00 |
| Revenue This Year | $15.22 | $1,208.75 |
| Revenue Next Year | $6.73 | N/A |
| P/E Ratio | $37.18 | ★ $4.83 |
| Revenue Growth | 20.69 | ★ 128.21 |
| 52 Week Low | $10.10 | $3.50 |
| 52 Week High | $13.75 | $5.45 |
| Indicator | GDOT | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 36.20 |
| Support Level | $11.95 | $4.10 |
| Resistance Level | $12.66 | $4.57 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 38.33 | 19.70 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for todays workforce.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.